Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx). The company is based on research from renowned professor Kristian Helin and dr. Karl Agger originating from Helin’s former research group at the University of Copenhagen. The ambition is to develop a treatment for acute myeloid leukaemia, which also holds potential for treatment of other types of cancer.